Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ARFGEF1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ARFGEF1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ARFGEF1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ARFGEF1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ARFGEF1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ARFGEF1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ARFGEF1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ARFGEF1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ARFGEF1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ARFGEF1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ARFGEF1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00064861 | Colorectum | FAP | protein glycosylation | 48/2622 | 226/18723 | 1.85e-03 | 1.57e-02 | 48 |
GO:00434131 | Colorectum | FAP | macromolecule glycosylation | 48/2622 | 226/18723 | 1.85e-03 | 1.57e-02 | 48 |
GO:00700851 | Colorectum | FAP | glycosylation | 50/2622 | 240/18723 | 2.30e-03 | 1.85e-02 | 50 |
GO:0009101 | Colorectum | FAP | glycoprotein biosynthetic process | 63/2622 | 317/18723 | 2.31e-03 | 1.86e-02 | 63 |
GO:0090303 | Colorectum | FAP | positive regulation of wound healing | 17/2622 | 59/18723 | 2.33e-03 | 1.87e-02 | 17 |
GO:00070155 | Colorectum | CRC | actin filament organization | 104/2078 | 442/18723 | 4.75e-14 | 7.12e-11 | 104 |
GO:00329705 | Colorectum | CRC | regulation of actin filament-based process | 89/2078 | 397/18723 | 5.25e-11 | 3.14e-08 | 89 |
GO:00071634 | Colorectum | CRC | establishment or maintenance of cell polarity | 57/2078 | 218/18723 | 3.96e-10 | 1.58e-07 | 57 |
GO:00510563 | Colorectum | CRC | regulation of small GTPase mediated signal transduction | 69/2078 | 302/18723 | 3.34e-09 | 9.08e-07 | 69 |
GO:00432545 | Colorectum | CRC | regulation of protein-containing complex assembly | 87/2078 | 428/18723 | 1.38e-08 | 2.67e-06 | 87 |
GO:19029035 | Colorectum | CRC | regulation of supramolecular fiber organization | 80/2078 | 383/18723 | 1.52e-08 | 2.75e-06 | 80 |
GO:00329565 | Colorectum | CRC | regulation of actin cytoskeleton organization | 76/2078 | 358/18723 | 1.68e-08 | 2.79e-06 | 76 |
GO:00300104 | Colorectum | CRC | establishment of cell polarity | 40/2078 | 143/18723 | 2.09e-08 | 3.23e-06 | 40 |
GO:01100535 | Colorectum | CRC | regulation of actin filament organization | 63/2078 | 278/18723 | 2.21e-08 | 3.23e-06 | 63 |
GO:00325354 | Colorectum | CRC | regulation of cellular component size | 79/2078 | 383/18723 | 3.30e-08 | 4.60e-06 | 79 |
GO:00322715 | Colorectum | CRC | regulation of protein polymerization | 55/2078 | 233/18723 | 3.97e-08 | 5.28e-06 | 55 |
GO:00512585 | Colorectum | CRC | protein polymerization | 64/2078 | 297/18723 | 1.26e-07 | 1.45e-05 | 64 |
GO:00072653 | Colorectum | CRC | Ras protein signal transduction | 70/2078 | 337/18723 | 1.49e-07 | 1.66e-05 | 70 |
GO:00081545 | Colorectum | CRC | actin polymerization or depolymerization | 51/2078 | 218/18723 | 1.65e-07 | 1.72e-05 | 51 |
GO:00300415 | Colorectum | CRC | actin filament polymerization | 45/2078 | 191/18723 | 6.99e-07 | 4.61e-05 | 45 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARFGEF1 | SNV | Missense_Mutation | novel | c.5458C>T | p.Arg1820Cys | p.R1820C | Q9Y6D6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
ARFGEF1 | SNV | Missense_Mutation | novel | c.3063N>C | p.Lys1021Asn | p.K1021N | Q9Y6D6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ARFGEF1 | SNV | Missense_Mutation | | c.2723G>A | p.Arg908Lys | p.R908K | Q9Y6D6 | protein_coding | tolerated(0.33) | benign(0.241) | TCGA-A2-A0ET-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
ARFGEF1 | SNV | Missense_Mutation | | c.4345N>A | p.Glu1449Lys | p.E1449K | Q9Y6D6 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A2-A1FV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD |
ARFGEF1 | SNV | Missense_Mutation | | c.571N>A | p.Gln191Lys | p.Q191K | Q9Y6D6 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-A2-A4S3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARFGEF1 | SNV | Missense_Mutation | | c.2710N>A | p.Glu904Lys | p.E904K | Q9Y6D6 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARFGEF1 | SNV | Missense_Mutation | novel | c.1879A>G | p.Ser627Gly | p.S627G | Q9Y6D6 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-A8-A09E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
ARFGEF1 | SNV | Missense_Mutation | | c.3227N>C | p.Arg1076Thr | p.R1076T | Q9Y6D6 | protein_coding | tolerated(0.22) | benign(0.039) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ARFGEF1 | SNV | Missense_Mutation | rs751084276 | c.92N>G | p.Ser31Cys | p.S31C | Q9Y6D6 | protein_coding | deleterious(0.02) | possibly_damaging(0.784) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ARFGEF1 | SNV | Missense_Mutation | | c.158N>T | p.Pro53Leu | p.P53L | Q9Y6D6 | protein_coding | tolerated(0.1) | benign(0.18) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |